NCT02564939

Brief Summary

Delirium is a common morbid condition in hospitalized adults. Treatment of delirium has been unsatisfactory and prevention is the preferred goal. Based on limited experimental research, ramelteon appears to have promise for prevention. This study will evaluate ramelteon in prevention of delirium in a hospitalized adult population age 65+ in a double-blinded RCT.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
240

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Feb 2017

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 1, 2015

Completed
1.4 years until next milestone

Study Start

First participant enrolled

February 23, 2017

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

August 1, 2018

Status Verified

July 1, 2018

Enrollment Period

1.8 years

First QC Date

September 29, 2015

Last Update Submit

July 31, 2018

Conditions

Keywords

prevention

Outcome Measures

Primary Outcomes (1)

  • delirium

    delirium as determined by CAM screening and expert review

    through study completion, anticipate completion at 1 year

Study Arms (2)

ramelteon

ACTIVE COMPARATOR

receive ramelteon

Drug: ramelteon

placebo

PLACEBO COMPARATOR

receive placebo

Drug: Placebo

Interventions

double-blind RCT

Also known as: Rozerem
ramelteon

double-blind RCT

placebo

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • from designated nursing units

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hartford Hospital

Hartford, Connecticut, 06102, United States

RECRUITING

MeSH Terms

Conditions

Delirium

Interventions

ramelteon

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Study Officials

  • Robert S Dicks, MD

    Hartford Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

christine waszynski, APRN

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director Geriatrics

Study Record Dates

First Submitted

September 29, 2015

First Posted

October 1, 2015

Study Start

February 23, 2017

Primary Completion

December 1, 2018

Study Completion

June 1, 2019

Last Updated

August 1, 2018

Record last verified: 2018-07

Locations